Boehringer and MD Anderson extend KRAS cancer collaborationBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring Share XBoehringer and MD Anderson extend KRAS cancer collaborationhttps://pharmaphorum.com/news/boehringer-and-md-anderson-extend-kras-cancer-collaboration/
COVID-19 drives Boehringer’s R&D spend to record level in 2020Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised Share XCOVID-19 drives Boehringer’s R&D spend to record level in 2020https://pharmaphorum.com/news/covid-19-drives-boehringers-rd-spend-to-record-level-in-2020/
No cooling off for pharma digital transformation in 2021COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life Share XNo cooling off for pharma digital transformation in 2021https://pharmaphorum.com/views-analysis-digital/no-cooling-off-for-pharma-digital-transformation-in-2021/
BI investigates cancer ‘dark antigens’ with UK’s EnaraBoehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight Share XBI investigates cancer ‘dark antigens’ with UK’s Enarahttps://pharmaphorum.com/news/boehringer-to-investigate-dark-antigens-with-uk-cancer-specialist-enara/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
Boehringer axes IPF deal with South Korea’s Bridge Biotherapeutics over toxicity concernsBoehringer Ingelheim and South Korea’s Bridge Biotherapeutics have decided to axe their collaboration over a potential new drug Share XBoehringer axes IPF deal with South Korea’s Bridge Biotherapeutics over toxicity concernshttps://pharmaphorum.com/news/boehringer-axes-ipf-deal-with-south-koreas-bridge-therapeutics-over-toxicity-concerns/
Boehringer, Yale trial digital tech in heart failurePatients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a Share XBoehringer, Yale trial digital tech in heart failurehttps://pharmaphorum.com/news/boehringer-yale-trial-digital-tech-in-heart-failure/
BI signs schizophrenia app deal with Click TherapeuticsBoehringer Ingelheim has signed a $500 million contract with Click Therapeutics to co-develop and market a digital treatment Share XBI signs schizophrenia app deal with Click Therapeuticshttps://pharmaphorum.com/news/bi-signs-schizophrenia-app-deal-with-click-therapeutics/
